Adaptive Biotechnologies(US:ADPT) Globenewswireยท2025-04-10 20:05Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q1 2025 on May 1, 2025, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] - The company focuses on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [3] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company that aims to leverage the adaptive immune system for disease diagnosis and treatment [3] - The company utilizes a proprietary immune medicine platform to decode the genetics of the adaptive immune system, enabling partnerships with biopharmaceutical companies and the development of clinical diagnostics [3] - The business segments include Minimal Residual Disease (MRD) and Immune Medicine, targeting diseases such as cancer and autoimmune disorders [3] Investor Relations - For investor inquiries, the Vice President of Investor Relations and FP&A is Karina Calzadilla, reachable at 201-396-1687 [4] - Media inquiries can be directed to Erica Jones, Associate Director of Corporate Communications, at 845-344-7542 [4]